Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.

Humana (HUM) backs reforms on extra Medicare Advantage payments from home visits and chart review. Read more here.

Due to the sharp price decline, the yield from the stock's dividend has climbed to 2.8%, which is higher than the S&P 500 ...

The health insurer has suffered mounting problems and backlash since the fatal shooting of former CEO Brian Thompson.

Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...

UnitedHealth Group Incorporated’s UNH new CEO, Steve Hemsley, began his return to leadership by issuing a rare apology to ...